Navigating 2026: The Top Health Technology Trends Every Leader Should Watch — Part 11
Imagine pitching a breakthrough medical technology to a hospital executive. The clinical evidence is compelling. Physicians are enthusiastic. The technology could significantly improve patient care.
Then comes the question that determines if the conversation moves forward: What will it save us?
Across medical devices, biopharmaceuticals, diagnostics, and digital health, affordability is becoming impossible to ignore. Healthcare organizations are wrestling with higher operating costs, reimbursement uncertainty, rising drug expenditures, and growing demands to demonstrate measurable returns on investment.
The scale of the challenge is staggering. According to an October 2026 analysis by KFF, U.S. healthcare spending is projected to reach $6 trillion this year, representing 18.7% of the nation’s economy. By 2034, spending could approach $9 trillion, or more than one-fifth of GDP.¹
Behind these figures is a convergence of economic and demographic pressures: rising labor, energy, and supply costs; an aging population requiring more complex, chronic care; trade and supply-chain uncertainty; and growing use of expensive pharmaceuticals and specialty treatments. Meanwhile, reimbursement constraints, medical debt, and financial pressures on patients and employers are testing the system’s capacity to absorb additional costs.
For health technology leaders, this creates a fundamental challenge: How do you effectively commercialize breakthrough innovations when customers, payers, and patients are struggling to afford what’s already available?
The answer demands more than cost-cutting. It requires rethinking how healthcare innovation is designed, delivered, measured, and supported by the people behind it.
The affordability squeeze is reshaping the market
Healthcare affordability has always been a concern. What’s different in 2026 is how thoroughly cost considerations are influencing business decisions across the industry.
As Steven Wardell, founder of Wardell Advisors, explained during his two-part Serious Talent® Chat discussion on healthcare budgets, the market for health technology is far from monolithic. Hospitals, insurers, employers, life sciences companies and consumers each operate within different financial realities, with distinct decisionmakers, spending priorities and expectations for technology investments.²
Wardell highlighted a particularly important challenge for emerging health tech companies: The budget available for new technology is often only a small fraction of an enterprise’s overall spending. Winning that investment requires understanding the buyer’s most pressing financial and operational problems, not simply demonstrating an innovative solution.
These dynamics play out differently across the industry:
• Medical device manufacturers face increasingly selective buyers and investors. Hospitals scrutinize capital expenditures, supplies, maintenance, and training costs. Meanwhile, EY’s latest industry analysis found that medtech mergers and acquisitions increased in 2026 even as valuations declined during the first half of the year, reflecting a market increasingly focused on strategic portfolio priorities.³
• Diagnostics companies are confronting direct reimbursement pressure. In October, Labcorp and Quest Diagnostics urged Congress to address scheduled 2027 laboratory payment cuts. Labcorp estimated a potential $125 million revenue impact, illustrating how reimbursement decisions can materially affect even established industry leaders.⁴
• Healthcare providers are weighing innovation against financial survival. An October American Hospital Association report found that more than 40% of rural hospitals operate at a financial loss, threatening access to care in already underserved communities.⁵
• Employers and health plans are demanding greater value from their investments. An August Business Group on Health survey found that large employers anticipate a median 9.2% increase in healthcare spending in 2027. As purchasing budgets tighten, employers are becoming more selective about the benefits and technologies they support.⁶
• Biopharmaceutical companies face changing economics of innovation and access. Growing demand for specialty therapies, including treatments for chronic conditions, is increasing pressure on drug spending, while pricing policies and generic and biosimilar competition are reshaping commercial strategies.
These pressures extend to patients. A September 2026 KFF survey found that 36% of adults under 65 with three or more chronic conditions had gone without needed healthcare in the previous year because of cost.⁷ Such affordability challenges can delay treatment, complicate disease management and create further pressures throughout the healthcare system.
Together, these developments illustrate the fact that affordability should affect every stage of healthcare innovation, from initial product development to commercialization and long-term adoption. Today’s executives can’t just focus on whether their technologies work but must continuously ask whether they deliver sufficient value within the economic realities of our healthcare system.
From cool innovation to clear value
A device that improves diagnostic accuracy is valuable. But what if it also reduces repeat testing, eliminates unnecessary appointments or helps clinicians identify problems before they require expensive interventions?
That’s a more compelling proposition for a financially constrained buyer.
Distinctions like these are increasingly important when the market is moving toward performance-based purchasing. A September 2026 survey from the Peterson Health Technology Institute found that 68% of employers and 55% of health plans now use performance-based contracts for digital health solutions. Among purchasers using these arrangements, 85% place at least one-quarter of the contract fees at risk based on performance.⁸
In other words, buyers increasingly want healthtech companies to share accountability for results.
Lauren Seno, COO of Charm Economics, reinforced this challenge during her Serious Talent® Chat, “Prove It: Why Economic Evidence Is the New Prerequisite for Adoption.” Clinical evidence may show whether a technology works, but demonstrating its economic value requires understanding cost offsets, return on investment, budget impact, and the priorities of individual purchasers.
Her advice: Start developing that economic case as early as possible, and keep strengthening it as the organization and its evidence mature. Create collaboration among clinical researchers, product developers, health economists, reimbursement specialists, and commercial teams early on and don’t wait until you’re ready for commercialization to confront healthcare economic issues.⁹
Competition and policy are changing the pharmaceutical affordability equation
Few areas illustrate the tension between innovation and affordability as clearly as pharmaceuticals.
Advanced biologics, specialty medicines, and precision therapies offer enormous potential for patients. Yet their development and commercialization can carry substantial costs, raising difficult questions about pricing, access, and long-term sustainability.
Generic and biosimilar competition provides one important counterweight.
The Association for Accessible Medicines reported in September that generic and biosimilar medicines generated approximately $496 billion in U.S. healthcare savings during 2025. These medicines represented 89% of prescriptions dispensed but just 12% of prescription drug spending.¹⁰
The savings are substantial, but the economics are complicated. Manufacturers of lower-cost medicines face pricing pressures, market-access barriers and operational challenges that can threaten the sustainability of affordable alternatives.
Meanwhile, government policy is introducing additional considerations for innovative manufacturers. In September, the Centers for Medicare & Medicaid Services finalized the GLOBE Model, which will test a new approach to Medicare Part B drug payment rebates using international pricing benchmarks.¹¹
For biopharmaceutical executives, navigating these developments requires a multidimensional approach: thoughtful portfolio management, stronger evidence of therapeutic value, manufacturing efficiency, and pricing strategies that account for access as well as innovation.
The companies best positioned for the future may be those that can align scientific progress with sustainable economics throughout the product lifecycle.
Can AI help bend the cost curve?
Artificial intelligence has appeared repeatedly throughout our Navigating 2026 series. Affordability brings the conversation to one of its most practical questions: Can AI help healthcare organizations operate more efficiently?
Recent research suggests that it can, although returns vary considerably by application.
A September 2026 study from Bain & Company and KLAS found that healthcare providers and payers continue investing in information technology despite financial pressures. Purchasers increasingly expect returns of at least three times their investment, along with measurable results and relatively short timeframes for realizing value.¹²
Medical device manufacturers want AI to support production planning, quality assurance, and service operations, among other needs. Biopharmaceutical companies can evaluate applications in research, regulatory documentation, and manufacturing. Diagnostics providers may find opportunities in laboratory operations and workflow optimization. Digital health companies can use AI to scale their offerings and manage clinical risks.
But successful implementation requires discipline. An AI application that saves employees several minutes per task may sound attractive. Whether it creates meaningful financial value depends on implementation costs, integration requirements, oversight, and how the recovered capacity is then reinvested.
Leaders should prioritize use cases with measurable operational outcomes, establish clear accountability, and ensure their teams understand how to properly translate technology investments into sustainable improvements without introducing new risks.
They can’t be mesmerized by the shiny object that is AI and lose sight of important goals like making their innovation more productive, accessible, and economically defensible.
Five strategic priorities for health tech leaders
As affordability pressures intensify, several practical strategies can help organizations protect their competitiveness without sacrificing their capacity to innovate.
None of these strategies offers a universal solution. Together, however, they provide a framework for turning financial pressure into an opportunity for smarter innovation.
The talent dimension
A company can develop breakthrough medical technology, secure regulatory clearance, and generate enthusiasm among clinicians, yet still struggle to gain commercial traction.
The problem may have little to do with the innovation itself. Perhaps the company underestimated reimbursement hurdles, failed to anticipate the cost of integrating its technology into clinical workflows, or simply couldn’t demonstrate a compelling financial return for customers.
These are gaps in expertise, leadership, execution, and collaboration. And in an increasingly cost-conscious market, those gaps can be killers.
Product leaders must understand the economic constraints facing customers. Commercial professionals need fluency in clinical and financial outcomes. Finance and operations leaders must identify efficiencies without compromising quality. Regulatory and market-access specialists play an increasingly important role in commercialization strategy.
And executives must build a culture in which these capabilities work together.
At Talencio, we see this as an important consideration for organizations planning their next stage of growth. The right talent strategy isn’t simply about filling positions. It’s about identifying the combination of expertise, adaptability, and leadership needed to advance innovation in a more demanding market.
In many cases, that may mean bringing in specialized expertise at critical stages of the company’s growth. In others, it may mean developing existing leaders or rethinking how teams collaborate across functions.
The specific play call may differ, but affordability is ultimately a team sport. Organizations that navigate it successfully will be those that connect scientific ambition with operational discipline and market realities.
Looking beyond 2026
Over the past year, our Navigating 2026 series has explored forces reshaping health technology, from AI and new care delivery models to precision medicine, interoperability, cybersecurity, continuous monitoring, and supply-chain resilience.
Despite their differences, these trends share a common theme: Technological progress is accelerating, but capturing its value is becoming more complex.
Affordability brings that challenge into sharp focus.
The next generation of successful health technology companies won’t be defined by the most sophisticated products, biggest budgets, or fastest pace of innovation. They’ll distinguish themselves by making meaningful advances accessible, sustainable, and valuable to the healthcare organizations and patients they serve.
Shape your competitive advantage well into the future.
Sources
- KFF, How Much Is Health Spending Expected to Grow? (Oct 22, 2026)
3. MedTech Dive, 3 Highlights from EY’s Report on 2026 Medtech Trends (Oct 29, 2026)
4. MedTech Dive, Labcorp, Quest Urge RESULTS Act Passage as Lab Payment Cuts Loom (Oct 30, 2026)
6. Healthcare Dive, Employers Face ‘Existential Reckoning’ as Health Costs Surge (Aug 26, 2026)
About the Author
Paula Norbom
is the Founder and CEO of Talencio, an executive search and staffing firm serving health technology companies. She has worked in the health technology industry for over 30 years.